Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Renal Insufficiency, Chronic 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Docetaxel 43enzalutamide 31Prednisone 25Abiraterone Acetate 24Magnetic Resonance Spectroscopy 18abiraterone 15pembrolizumab 14bicalutamide 14Radiotherapy 14Cyclophosphamide 13darolutamide 12Leuprolide 12Goserelin 12apalutamide 10Ipilimumab 10olaparib 9Specimen Handling 9Radiosurgery 9Radiation 9Injections 9Biopsy 9Pluvicto 8Paclitaxel 8Radiotherapy, Intensity-Modulated 7Carboplatin 7sargramostim 6fludarabine 6cabazitaxel 6Sirolimus 6Nivolumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Prostatic Neoplasms × saponin QA-21V1 × Clear all
NCT00036933 2013-03-25

Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
9 enrolled
Genitourinary

Prostatic Neoplasms

NCT00003819 2013-03-19

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
21 enrolled
Genitourinary

Prostatic Neoplasms

NCT00004929 2013-01-31

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
15 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡